Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07623655 | CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia | not yet recruiting | — | 107 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07624760 | Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging(MGUS-PET) | not yet recruiting | N/A | 50 | University of ZurichOTHER | 1 | Jun 3, 2026 |
| clinicaltrials |
| NCT07624799 | Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).(PACIFIC) | not yet recruiting | Phase 2 | 82 | French Innovative Leukemia OrganisationOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07614035 | Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma(ASCLEPIO) | not yet recruiting | — | 70 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors(FXS0683-001) | not yet recruiting | Phase 1 | 228 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07611149 | Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma | not yet recruiting | Phase 1 | 12 | Kure Cells, INCINDUSTRY | 0 | May 28, 2026 | clinicaltrials |
| NCT05700448 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 3 | 150 | CStone PharmaceuticalsINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07608549 | FLASH Pilot Phase 1 Safety Study | not yet recruiting | N/A | 10 | Lesley A. JarvisOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07609355 | AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma(GLORIA) | not yet recruiting | N/A | 25 | Sun Yat-sen UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609446 | Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma | not yet recruiting | — | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | not yet recruiting | Phase 1 | 20 | GlaxoSmithKlineINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07575893 | CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma(REACH-CD30) | not yet recruiting | Phase 1 | 12 | New York Medical CollegeOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.(FC-BALANCE) | not yet recruiting | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07586709 | In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms | not yet recruiting | Early Phase 1 | 18 | Liping DouOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 50 | University of NebraskaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Early Phase 1 | 9 | Ruijin HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 58 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 3 | 260 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07572175 | Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity(SPARTACUS) | not yet recruiting | Phase 2 | 60 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | not yet recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL(FRONTIER) | not yet recruiting | Phase 2 | 52 | Miltenyi Biomedicine GmbHINDUSTRY | 0 | May 6, 2026 | clinicaltrials |
| NCT07563543 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Early Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563023 | Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | not yet recruiting | Early Phase 1 | 6 | West China HospitalOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07546630 | Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542418 | Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial | not yet recruiting | N/A | 204 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT07538960 | Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. | not yet recruiting | — | 350 | Caja Costarricense de Seguro SocialOTHER_GOV | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539610 | Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors | not yet recruiting | Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Phase 1 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | not yet recruiting | Phase 2 | 36 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06617286 | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 21 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07476105 | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment | not yet recruiting | N/A | 170 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529223 | Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblastic Leukemia.(ASTRA) | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529405 | A Study of VG712 in Patients With Mycosis Fungoides(CurbMF) | not yet recruiting | Phase 2 | 386 | Virogen Biotechnology Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07525817 | A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma | not yet recruiting | — | 40 | Ou Bai, MD/PHDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT07511114 | A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping | not yet recruiting | Phase 3 | 156 | Ruijin HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07509385 | The Role of Serum Cytokines IL_17 A and IL_10 in Disease Activity of Acute B Lymphoblastic Leukemia in South Egypt | not yet recruiting | — | 80 | Assiut UniversityOTHER | 0 | Apr 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 3, 2026source: clinicaltrials